Chemical: Drug
amiodarone

PharmGKB contains no dosing guidelines for this . To report known genotype-based dosing guidelines, or if you are interested in developing guidelines, click here.


1. FDA Label for amiodarone

Full label available at DailyMed

Genes and/or phenotypes found in this label


PharmGKB contains no Clinical Variants that meet the highest level of criteria.

To see more Clinical Variants with lower levels of criteria, click the button at the bottom of the page.

Disclaimer: The PharmGKB's clinical annotations reflect expert consensus based on clinical evidence and peer-reviewed literature available at the time they are written and are intended only to assist clinicians in decision-making and to identify questions for further research. New evidence may have emerged since the time an annotation was submitted to the PharmGKB. The annotations are limited in scope and are not applicable to interventions or diseases that are not specifically identified.

The annotations do not account for individual variations among patients, and cannot be considered inclusive of all proper methods of care or exclusive of other treatments. It remains the responsibility of the health-care provider to determine the best course of treatment for a patient. Adherence to any guideline is voluntary, with the ultimate determination regarding its application to be made solely by the clinician and the patient. PharmGKB assumes no responsibility for any injury or damage to persons or property arising out of or related to any use of the PharmGKB clinical annotations, or for any errors or omissions.

? = Mouse-over for quick help

The table below contains information about pharmacogenomic variants on PharmGKB. Please follow the link in the "Variant" column for more information about a particular variant. Each link in the "Variant" column leads to the corresponding PharmGKB Variant Page. The Variant Page contains summary data, including PharmGKB manually curated information about variant-drug pairs based on individual PubMed publications. The PMIDs for these PubMed publications can be found on the Variant Page.

The tags in the first column of the table indicate what type of information can be found on the corresponding Variant Page.

Links in the "Gene" column lead to PharmGKB Gene Pages.

List of all variant annotations for amiodarone

Gene ? Variant?
(147)
Alternate Names ? Chemicals ? Alleles ?
(+ chr strand)
Function ? Amino Acid?
Translation
No VIP available CA VA
rs10800397 NC_000001.10:g.162237090C>T, NC_000001.11:g.162267300C>T, NG_015979.1:g.202510C>T, NM_001164757.1:c.178-20044C>T, NM_014697.2:c.178-20044C>T
C > T
SNP
No VIP available CA VA
rs10919035 NC_000001.10:g.162244012C>T, NC_000001.11:g.162274222C>T, NG_015979.1:g.209432C>T, NM_001164757.1:c.178-13122C>T, NM_014697.2:c.178-13122C>T, rs59698906
C > T
SNP
rs12720441 NC_000007.13:g.150647304G>A, NC_000007.13:g.150647304G>C, NC_000007.14:g.150950216G>A, NC_000007.14:g.150950216G>C, NG_008916.1:g.32711C>G, NG_008916.1:g.32711C>T, NM_000238.3:c.2350C>G, NM_000238.3:c.2350C>T, NM_001204798.1:c.1330C>G, NM_001204798.1:c.1330C>T, NM_172056.2:c.2350C>G, NM_172056.2:c.2350C>T, NM_172057.2:c.1330C>G, NM_172057.2:c.1330C>T, NP_000229.1:p.Arg784Gly, NP_000229.1:p.Arg784Trp, NP_001191727.1:p.Arg444Gly, NP_001191727.1:p.Arg444Trp, NP_742053.1:p.Arg784Gly, NP_742053.1:p.Arg784Trp, NP_742054.1:p.Arg444Gly, NP_742054.1:p.Arg444Trp, XM_011516185.1:c.2050C>G, XM_011516185.1:c.2050C>T, XM_011516186.1:c.2350C>G, XM_011516186.1:c.2350C>T, XP_011514487.1:p.Arg684Gly, XP_011514487.1:p.Arg684Trp, XP_011514488.1:p.Arg784Gly, XP_011514488.1:p.Arg784Trp, rs45607339
G > A
G > C
SNP
R784G/W
No VIP available CA VA
rs1805128 NC_000021.8:g.35821680C>T, NC_000021.9:g.34449382C>T, NG_009091.1:g.66934G>A, NM_000219.3:c.253G>A, NM_000219.5:c.253G>A, NM_001127668.3:c.253G>A, NM_001127669.3:c.253G>A, NM_001127670.1:c.253G>A, NM_001127670.3:c.253G>A, NM_001270402.2:c.253G>A, NM_001270403.2:c.253G>A, NM_001270404.2:c.253G>A, NM_001270405.2:c.253G>A, NP_000210.2:p.Asp85Asn, NP_001121140.1:p.Asp85Asn, NP_001121141.1:p.Asp85Asn, NP_001121142.1:p.Asp85Asn, NP_001257331.1:p.Asp85Asn, NP_001257332.1:p.Asp85Asn, NP_001257333.1:p.Asp85Asn, NP_001257334.1:p.Asp85Asn, XM_005260972.1:c.316G>A, XM_005260973.1:c.13+6004G>A, XM_011529555.1:c.13+6004G>A, XM_011529557.1:c.279+9272G>A, XP_005261029.1:p.Asp106Asn, rs17173507, rs52820407
C > T
SNP
D85N
No VIP available No Clinical Annotations available VA
rs7295250 NC_000012.11:g.2776943T>C, NC_000012.12:g.2667777T>C, NG_008801.2:g.701992T>C, NM_000719.6:c.4623+995T>C, NM_001129827.1:c.4767+995T>C, NM_001129829.1:c.4689+995T>C, NM_001129830.1:c.4623+995T>C, NM_001129830.2:c.4623+995T>C, NM_001129831.1:c.4707+995T>C, NM_001129832.1:c.4683+995T>C, NM_001129833.1:c.4623+995T>C, NM_001129834.1:c.4623+995T>C, NM_001129835.1:c.4623+995T>C, NM_001129836.1:c.4674+995T>C, NM_001129837.1:c.4590+995T>C, NM_001129838.1:c.4590+995T>C, NM_001129839.1:c.4584+995T>C, NM_001129840.1:c.4623+995T>C, NM_001129841.1:c.4623+995T>C, NM_001129842.1:c.4623+995T>C, NM_001129843.1:c.4623+995T>C, NM_001129844.1:c.4614+995T>C, NM_001129846.1:c.4590+995T>C, NM_001167623.1:c.4623+995T>C, NM_001167624.2:c.4623+995T>C, NM_001167625.1:c.4590+995T>C, NM_199460.3:c.4767+995T>C, XM_005253765.1:c.4917+995T>C, XM_005253766.1:c.4776+995T>C, XM_005253767.1:c.4599+995T>C, XM_005253768.1:c.4776+995T>C, XM_005253769.1:c.4698+995T>C, XM_005253770.1:c.4632+995T>C, XM_005253771.1:c.4632+995T>C, XM_005253772.1:c.4716+995T>C, XM_005253773.1:c.4692+995T>C, XM_005253774.1:c.4632+995T>C, XM_005253775.1:c.4632+995T>C, XM_005253776.1:c.4632+995T>C, XM_005253777.1:c.4683+995T>C, XM_005253778.1:c.4599+995T>C, XM_005253779.1:c.4599+995T>C, XM_005253780.1:c.4593+995T>C, XM_005253781.1:c.4632+995T>C, XM_005253782.1:c.4632+995T>C, XM_005253783.1:c.4632+995T>C, XM_005253784.1:c.4632+995T>C, XM_005253785.1:c.4632+995T>C, XM_005253786.1:c.4623+995T>C, XM_005253787.1:c.4599+995T>C, XM_005253788.1:c.2529+995T>C, XM_006719017.1:c.4713+995T>C, XM_011521017.1:c.3867+995T>C, XM_011521018.1:c.3312+995T>C, XM_011521019.1:c.1422+995T>C, XM_011521020.1:c.4788+995T>C, XM_011521021.1:c.4623+995T>C, XM_011521022.1:c.4623+995T>C, XM_011521023.1:c.4698+995T>C, rs17761221, rs60758963
T > C
SNP
Alleles, Functions, and Amino Acid Translations are all sourced from dbSNP 147

Overview

Generic Names
  • Amiodarona [INN-Spanish]
  • Amiodarone Base
  • Amiodarone HCL
  • Amiodarone Hydrochloride
  • Amiodaronum [INN-Latin]
Trade Names
  • Aminodarone
  • Amio-Aqueous IV
  • Amiodarons
  • Aratac
  • Arycor
  • Cordarone
  • Cordarone Intravenous
  • Labaz
  • Pacerone
  • pms-Amiodarone
Brand Mixture Names

PharmGKB Accession Id

PA448383

Type(s):

Drug

Description

An antianginal and antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting Na,K-activated myocardial adenosine triphosphatase. There is a resulting decrease in heart rate and in vascular resistance.

Source: Drug Bank

Indication

Intravenously, for initiation of treatment and prophylaxis of frequently recurring ventricular fibrillation and hemodynamically unstable ventricular tachycardia in patients refractory to other therapy. Orally, for the treatment of life-threatening recurrent ventricular arrhythmias such as recurrent ventricular fibrillation and recurrent hemodynamically unstable ventricular tachycardia.

Source: Drug Bank

Other Vocabularies

Information pulled from DrugBank has not been reviewed by PharmGKB.

Pharmacology, Interactions, and Contraindications

Mechanism of Action

The antiarrhythmic effect of amiodarone may be due to at least two major actions. It prolongs the myocardial cell-action potential (phase 3) duration and refractory period and acts as a noncompetitive a- and b-adrenergic inhibitor.

Source: Drug Bank

Pharmacology

Amiodarone belongs to a class of drugs called Vaughan-Williams Class III antiarrhythmic agents. It is used in the treatment of a wide range of cardiac tachyarhthmias, including both ventricular and supraventricular (atrial) arrhythmias. After intravenous administration in man, amiodarone relaxes vascular smooth muscle, reduces peripheral vascular resistance (afterload), and slightly increases cardiac index. Amiodarone prolongs phase 3 of the cardiac action potential. It has numerous other effects however, including actions that are similar to those of antiarrhythmic classes Ia, II, and IV. Amiodarone shows beta blocker-like and calcium channel blocker-like actions on the SA and AV nodes, increases the refractory period via sodium- and potassium-channel effects, and slows intra-cardiac conduction of the cardiac action potential, via sodium-channel effects.

Source: Drug Bank

Food Interaction

Grapefruit and grapefruit juice should be avoided throughout treatment.|Grapefruit can significantly increase serum levels of this product.|Take without regard to meals.

Source: Drug Bank

Absorption, Distribution, Metabolism, Elimination & Toxicity

Biotransformation

Amiodarone is extensively metabolized in the liver via CYP2C8 (under 1% unchanged in urine), and can effect the metabolism of numerous other drugs. The major metabolite of amiodarone is desethylamiodarone (DEA), which also has antiarrhythmic properties. The metabolism of amiodarone is inhibited by grapefruit juice, leading to elevated serum levels of amiodarone.

Source: Drug Bank

Protein Binding

>96%

Source: Drug Bank

Absorption

Slow and variable (about 20 to 55% of an oral dose is absorbed).

Source: Drug Bank

Half-Life

58 days (range 15-142 days)

Source: Drug Bank

Toxicity

Intravenous, mouse: LD 50 = 178 mg/kg. Some side effects have a significant mortality rate: specifically, hepatitis, exacerbation of asthma and congestive failure, and pneumonitis.

Source: Drug Bank

Clearance

Source: Drug Bank

Route of Elimination

Amiodarone is eliminated primarily by hepatic metabolism and biliary excretion and there is negligible excretion of amiodarone or DEA in urine.

Source: Drug Bank

Chemical Properties

Chemical Formula

C25H29I2NO3

Source: Drug Bank

Isomeric SMILES

CCCCc1c(c2ccccc2o1)C(=O)c3cc(c(c(c3)I)OCCN(CC)CC)I

Source: OpenEye

Canonical SMILES

CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1

Source: Drug Bank

Average Molecular Weight

645.3116

Source: Drug Bank

Monoisotopic Molecular Weight

645.023680639

Source: Drug Bank

SMILES

CCCCC1=C(C(=O)C2=CC(I)=C(OCCN(CC)CC)C(I)=C2)C2=CC=CC=C2O1

Source: Drug Bank

InChI String

InChI=1S/C25H29I2NO3/c1-4-7-11-22-23(18-10-8-9-12-21(18)31-22)24(29)17-15-19(26)25(20(27)16-17)30-14-13-28(5-2)6-3/h8-10,12,15-16H,4-7,11,13-14H2,1-3H3

Source: Drug Bank

PharmGKB Curated Pathways

Pathways created internally by PharmGKB based primarily on literature evidence.

  1. Antiarrhythmic Pathway, Pharmacodynamics
    Pharmacodynamic pathway of antiarrhythmic drugs in a stylized cardiac myocyte.

Genes that are associated with this drug in PharmGKB's database based on (1) variant annotations, (2) literature review, (3) pathways or (4) information automatically retrieved from DrugBank, depending on the "evidence" and "source" listed below.

Curated Information ?

Drug Targets

Gene Description
ADRA1A (source: Drug Bank )
ADRB1 (source: Drug Bank )
CACNA1H (source: Drug Bank )
CACNA2D2 (source: Drug Bank )
KCNH2 (source: Drug Bank )

Drug Interactions

Interaction Description
amiodarone - acenocoumarol Increases the anticoagulant effect (source: Drug Bank )
amiodarone - acenocoumarol Amiodarone may increase the anticoagulant effect of acenocoumarol. (source: Drug Bank )
amiodarone - amprenavir The protease inhibitor increases the effect and toxicity of amiodarone (source: Drug Bank )
amiodarone - amprenavir The protease inhibitor, amprenavir, may increase the effect and toxicity of amiodarone. (source: Drug Bank )
amiodarone - anisindione Increases the anitcoagulant effect (source: Drug Bank )
amiodarone - anisindione Amiodarone may increase the anticoagulant effect of anisindione. (source: Drug Bank )
amiodarone - atazanavir Increased risk of cardiotoxicity/arrhythmias (source: Drug Bank )
amiodarone - atazanavir Increased risk of cardiotoxicity/arrhythmias (source: Drug Bank )
amiodarone - atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank )
amiodarone - atomoxetine The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank )
amiodarone - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - cisapride Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - clarithromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - clarithromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - cyclosporine Increases the effect and toxicity of cyclosporine (source: Drug Bank )
amiodarone - cyclosporine Increases the effect and toxicity of cyclosporine (source: Drug Bank )
amiodarone - dicumarol Increases the anticoagulant effect (source: Drug Bank )
amiodarone - dicumarol Amiodarone may increase the anticoagulant effect of dicumarol. (source: Drug Bank )
amiodarone - digoxin Increases the effect of digoxin (source: Drug Bank )
amiodarone - digoxin Increases the effect of digoxin (source: Drug Bank )
amiodarone - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - diltiazem Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - erythromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - erythromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - ethotoin Increases the effect of hydantoin (source: Drug Bank )
amiodarone - ethotoin Increases the effect of hydantoin (source: Drug Bank )
amiodarone - fentanyl Possible bradycardia, hypotension (source: Drug Bank )
amiodarone - fentanyl Possible bradycardia, hypotension (source: Drug Bank )
amiodarone - flecainide Increases the effect and toxicity of flecainide (source: Drug Bank )
amiodarone - flecainide Increases the effect and toxicity of flecainide (source: Drug Bank )
amiodarone - fosamprenavir The protease inhibitor increases the effect and toxicity of amiodarone (source: Drug Bank )
amiodarone - fosamprenavir The protease inhibitor, fosamprenavir, may increase the effect and toxicity of amiodarone. (source: Drug Bank )
amiodarone - fosphenytoin Increases the effect of hydantoin (source: Drug Bank )
amiodarone - fosphenytoin Increases the effect of hydantoin (source: Drug Bank )
amiodarone - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - gatifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - grepafloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - indinavir Indinavir increases the effect and toxicity of amiodarone (source: Drug Bank )
amiodarone - indinavir Indinavir increases the effect and toxicity of amiodarone (source: Drug Bank )
amiodarone - iohexol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - iohexol Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - levofloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - mephenytoin Increases the effect of hydantoin (source: Drug Bank )
amiodarone - mephenytoin Increases the effect of hydantoin (source: Drug Bank )
amiodarone - mesoridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - mesoridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - moxifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - moxifloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - nelfinavir Nelfinavirincreases the effect and toxicity of amiodarone (source: Drug Bank )
amiodarone - nelfinavir Nelfinavirincreases the effect and toxicity of amiodarone (source: Drug Bank )
amiodarone - phenytoin Increases the effect of hydantoin (source: Drug Bank )
amiodarone - phenytoin Increases the effect of hydantoin (source: Drug Bank )
amiodarone - procainamide Increases serum levels and toxicity of procainamide (source: Drug Bank )
amiodarone - procainamide Increases serum levels and toxicity of procainamide (source: Drug Bank )
amiodarone - quinidine Increases the effect of quinidine (source: Drug Bank )
amiodarone - quinidine Increases the effect of qiunidine (source: Drug Bank )
amiodarone - quinidine Increases the effect of qiunidine (source: Drug Bank )
amiodarone - ranolazine Possible additive effect on QT prolongation (source: Drug Bank )
amiodarone - ranolazine Possible additive effect on QT prolongation (source: Drug Bank )
amiodarone - rifampin Rifampin decreases the effect of amiodarone (source: Drug Bank )
amiodarone - rifampin Rifampin decreases the effect of amiodarone (source: Drug Bank )
amiodarone - ritonavir Ritonavir increases the effect and toxicity of amiodarone (source: Drug Bank )
amiodarone - ritonavir Ritonavir increases the effect and toxicity of amiodarone (source: Drug Bank )
amiodarone - saquinavir The protease inhibitor increases the effect and toxicity of amiodarone (source: Drug Bank )
amiodarone - saquinavir The protease inhibitor, saquinavir, may increase the effect and toxicity of amiodarone. (source: Drug Bank )
amiodarone - simvastatin Increased risk of rhabdomyolysis (source: Drug Bank )
amiodarone - simvastatin Increased risk of rhabdomyolysis (source: Drug Bank )
amiodarone - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - sparfloxacin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - telithromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - telithromycin Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - terfenadine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - thioridazine Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - vardenafil Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - vardenafil Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - warfarin Increases the anticoagulant effect (source: Drug Bank )
amiodarone - warfarin Amiodarone may increase the anticoagulant effect of warfarin. (source: Drug Bank )
amiodarone - ziprasidone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amiodarone - ziprasidone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
amprenavir - amiodarone The protease inhibitor increases the effect and toxicity of amiodarone (source: Drug Bank )
amprenavir - amiodarone The protease inhibitor, amprenavir, may increase the effect and toxicity of amiodarone. (source: Drug Bank )
atazanavir - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
atazanavir - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
atomoxetine - amiodarone The CYP2D6 inhibitor could increase the effect and toxicity of atomoxetine (source: Drug Bank )
cisapride - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
cisapride - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
clarithromycin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
clarithromycin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
cyclosporine - amiodarone Amiodarone increases the effect and toxicity of cyclosporine (source: Drug Bank )
cyclosporine - amiodarone Amiodarone increases the effect and toxicity of cyclosporine (source: Drug Bank )
digoxin - amiodarone Amiodarone increases the effect of digoxin (source: Drug Bank )
digoxin - amiodarone Amiodarone increases the effect of digoxin (source: Drug Bank )
diltiazem - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
diltiazem - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
erythromycin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
erythromycin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
fentanyl - amiodarone Possible bradycardia, hypotension (source: Drug Bank )
flecainide - amiodarone Amiodarone increases the effect and toxicity of flecainide (source: Drug Bank )
flecainide - amiodarone Amiodarone increases the effect and toxicity of flecainide (source: Drug Bank )
fosamprenavir - amiodarone The protease inhibitor increases the effect and toxicity of amiodarone (source: Drug Bank )
fosamprenavir - amiodarone The protease inhibitor, fosamprenavir, may increase the effect and toxicity of amiodarone. (source: Drug Bank )
fosphenytoin - amiodarone Amiodarone increases the effect of hydantoin (source: Drug Bank )
gatifloxacin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
gatifloxacin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
grepafloxacin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
grepafloxacin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
indinavir - amiodarone Indinavir increases the effect and toxicity of amiodarone (source: Drug Bank )
indinavir - amiodarone Indinavir increases the effect and toxicity of amiodarone (source: Drug Bank )
levofloxacin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
levofloxacin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
mesoridazine - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
mesoridazine - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
moxifloxacin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
moxifloxacin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
nelfinavir - amiodarone Nelfinavir increases the effect and toxicity of amiodarone (source: Drug Bank )
nelfinavir - amiodarone Nelfinavir increases the effect and toxicity of amiodarone (source: Drug Bank )
phenytoin - amiodarone Amiodarone increases the effect of hydantoin (source: Drug Bank )
phenytoin - amiodarone Amiodarone increases the effect of hydantoin (source: Drug Bank )
procainamide - amiodarone Amiodarone increases serum levels and toxicity of procainamide (source: Drug Bank )
procainamide - amiodarone Amiodarone increases serum levels and toxicity of procainamide (source: Drug Bank )
quinidine - amiodarone Amiodarone increases the effect of quinidine (source: Drug Bank )
quinidine - amiodarone Amiodarone increases the effect of quinidine (source: Drug Bank )
ranolazine - amiodarone Possible additive effect on QT prolongation (source: Drug Bank )
rifampin - amiodarone Rifampin decreases the effect of amiodarone (source: Drug Bank )
rifampin - amiodarone Rifampin decreases the effect of amiodarone (source: Drug Bank )
tamoxifen - amiodarone Amiodarone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank )
tamoxifen - amiodarone Amiodarone may decrease the therapeutic effect of Tamoxifen by decreasing the production of active metabolites. Consider alternate therapy. (source: Drug Bank )
tamsulosin - amiodarone Amiodarone, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amiodarone is initiated, discontinued, or dose changed. (source: Drug Bank )
tamsulosin - amiodarone Amiodarone, a CYP3A4/2D6 inhibitor, may decrease the metabolism and clearance of Tamsulosin, a CYP3A4/2D6 substrate. Monitor for changes in therapeutic/adverse effects of Tamsulosin if Amiodarone is initiated, discontinued, or dose changed. (source: Drug Bank )
telithromycin - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
telithromycin - amiodarone Telithromycin may reduce clearance of Amiodarone. Consider alternate therapy or monitor for changes in the therapeutic/adverse effects of Amiodarone if Telithromycin is initiated, discontinued or dose changed. (source: Drug Bank )
terfenadine - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
terfenadine - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
thioridazine - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
thioridazine - amiodarone Increased risk of cardiotoxicity and arrhythmias (source: Drug Bank )
thiothixene - amiodarone May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
thiothixene - amiodarone May cause additive QTc-prolonging effects. Increased risk of ventricular arrhythmias. Consider alternate therapy. Thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
tipranavir - amiodarone Tipranavir, co-administered with Ritonavir, may increase the plasma concentration of Amiodarone. Concomitant therapy is contraindicated. (source: Drug Bank )
tizanidine - amiodarone Amiodarone may decrease the metabolism and clearance of Tizanidine. Consider alternate therapy or use caution during co-administration. (source: Drug Bank )
tolterodine - amiodarone Amiodarone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank )
tolterodine - amiodarone Amiodarone may decrease the metabolism and clearance of Tolterodine. Adjust Tolterodine dose and monitor for efficacy and toxicity. (source: Drug Bank )
topotecan - amiodarone The p-glycoprotein inhibitor, Amiodarone, may increase the bioavailability of oral Topotecan. A clinically significant effect is also expected with IV Topotecan. Concomitant therapy should be avoided. (source: Drug Bank )
toremifene - amiodarone Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Consider alternate therapy. A thorough risk:benefit assessment is required prior to co-administration. (source: Drug Bank )
tramadol - amiodarone Amiodarone may increase Tramadol toxicity by decreasing Tramadol metabolism and clearance. Amiodarone may decrease the effect of Tramadol by decreasing active metabolite production. (source: Drug Bank )
trazodone - amiodarone The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed. (source: Drug Bank )
trazodone - amiodarone The CYP3A4 inhibitor, Amiodarone, may increase Trazodone efficacy/toxicity by decreasing Trazodone metabolism and clearance. Monitor for changes in Trazodone efficacy/toxicity if Amiodarone is initiated, discontinued or dose changed. (source: Drug Bank )
trimipramine - amiodarone Additive QTc-prolongation may occur, increasing the risk of serious ventricular arrhythmias. Concomitant therapy should be used with caution. (source: Drug Bank )
verapamil - amiodarone Additive bradycardic effects may occur. One case report of sinus arrest has been reported. Monitor for changes in the therapeutic effect and signs of Verapamil toxicity if Amiodarone is initiated, discontinued or dose changed. (source: Drug Bank )
voriconazole - amiodarone Additive QTc prolongation may occur. Voriconazole, a strong CYP3A4 inhibitor, may increase the serum concentration of amiodarone by decreasing its metabolism. Consider alternate therapy or monitor for changes in the therapeutic and adverse effects of amiodarone if voriconazole is initiated, discontinued or dose changed. (source: Drug Bank )
vorinostat - amiodarone Additive QTc prolongation may occur. Consider alternate therapy or monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )
warfarin - amiodarone Amiodarone may increase the anticoagulant effect of warfarin. Monitor for changes in prothrombin time and therapeutic effects of warfarin if amiodarone is initiated, discontinued or dose changed. (source: Drug Bank )
ziprasidone - amiodarone Additive QTc-prolonging effects may increase the risk of severe arrhythmias. Concomitant therapy is contraindicated. (source: Drug Bank )
zuclopenthixol - amiodarone Additive QTc prolongation may occur. Consider alternate therapy or use caution and monitor for QTc prolongation as this can lead to Torsade de Pointes (TdP). (source: Drug Bank )

Curated Information ?

Relationships from National Drug File - Reference Terminology (NDF-RT)

May Treat
Contraindicated With

Publications related to amiodarone: 26

No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Liver injury with novel oral anticoagulants: assessing post-marketing reports in the US Food and Drug Administration Adverse Event Reporting System. British journal of clinical pharmacology. 2015. Raschi Emanuel, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanisms and assessment of statin-related muscular adverse effects. British journal of clinical pharmacology. 2014. Moßhammer Dirk, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
The genetics of pro-arrhythmic adverse drug reactions. British journal of clinical pharmacology. 2014. Petropoulou Evmorfia, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Pathway analysis of genome-wide data improves warfarin dose prediction. BMC genomics. 2013. Daneshjou Roxana, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Common variation in the NOS1AP gene is associated with drug-induced QT prolongation and ventricular arrhythmia. Journal of the American College of Cardiology. 2012. Jamshidi Yalda, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
A Large Candidate Gene Survey Identifies the KCNE1 D85N Polymorphism as a Possible Modulator of Drug-Induced Torsades de Pointes. Circulation. Cardiovascular genetics. 2011. Kääb Stefan, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
Very important pharmacogene summary: ABCB1 (MDR1, P-glycoprotein). Pharmacogenetics and genomics. 2011. Hodges Laura M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Genetic warfarin dosing tables versus algorithms. Journal of the American College of Cardiology. 2011. Finkelman Brian S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available VIP No VIP available
KCNH2 pharmacogenomics summary. Pharmacogenetics and genomics. 2010. Oshiro Connie, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Drug-induced long QT syndrome. Pharmacological reviews. 2010. Kannankeril Prince, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Extrapyramidal symptoms with concomitant use of amitriptyline and amiodarone in an elderly patient. The American journal of geriatric pharmacotherapy. 2010. Pawar Pritish S, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Coprescription of tamoxifen and medications that inhibit CYP2D6. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2010. Sideras Kostandinos, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin pharmacogenetics: a single VKORC1 polymorphism is predictive of dose across 3 racial groups. Blood. 2010. Limdi Nita A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
A polymorphism in the VKORC1 regulator calumenin predicts higher warfarin dose requirements in African Americans. Clinical pharmacology and therapeutics. 2010. Voora D, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Composite functional genetic and comedication CYP2D6 activity score in predicting tamoxifen drug exposure among breast cancer patients. Journal of clinical pharmacology. 2010. Borges Silvana, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Identification of novel substrates for human cytochrome P450 2J2. Drug metabolism and disposition: the biological fate of chemicals. 2010. Lee Caroline A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Human CYP2C8: structure, substrate specificity, inhibitor selectivity, inducers and polymorphisms. Current drug metabolism. 2009. Lai Xin-Sheng, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Warfarin interactions with substances listed in drug information compendia and in the FDA-approved label for warfarin sodium. Clinical pharmacology and therapeutics. 2009. Anthony M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation. Analytical and bioanalytical chemistry. 2008. Zanger Ulrich M, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Structure, function and regulation of P-glycoprotein and its clinical relevance in drug disposition. Xenobiotica; the fate of foreign compounds in biological systems. 2008. Zhou S-F. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Cytochrome P450 2C8: substrates, inhibitors, pharmacogenetics, and clinical relevance. Clinical pharmacology and therapeutics. 2005. Totah Rheem A, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Amiodarone N-deethylation by CYP2C8 and its variants, CYP2C8*3 and CYP2C8 P404A. Pharmacology & toxicology. 2002. Soyama Akiko, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Variant of SCN5A sodium channel implicated in risk of cardiac arrhythmia. Science (New York, N.Y.). 2002. Splawski Igor, et al. PubMed
No Dosing Guideline available No Drug Label available CA VA No VIP available No VIP available
Allelic variants in long-QT disease genes in patients with drug-associated torsades de pointes. Circulation. 2002. Yang Ping, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Inhibitory effects of antiarrhythmic drugs on phenacetin O-deethylation catalysed by human CYP1A2. British journal of clinical pharmacology. 1998. Kobayashi K, et al. PubMed
No Dosing Guideline available No Drug Label available No Clinical Annotation available No Variant Annotation available No VIP available No VIP available
Mechanism of warfarin potentiation by amiodarone: dose--and concentration--dependent inhibition of warfarin elimination. European journal of clinical pharmacology. 1985. Almog S, et al. PubMed

LinkOuts

Web Resource:
Wikipedia
National Drug Code Directory:
0703-1332-03
DrugBank:
DB01118
ChEBI:
2663
KEGG Compound:
C06823
KEGG Drug:
D02910
PubChem Compound:
2157
PubChem Substance:
159329
46507387
IUPHAR Ligand:
2566
Drugs Product Database (DPD):
2243836
BindingDB:
18957
ChemSpider:
2072
Therapeutic Targets Database:
DAP000496

Clinical Trials

These are trials that mention amiodarone and are related to either pharmacogenetics or pharmacogenomics.

No trials loaded.

NURSA Datasets

provided by nursa.org

No NURSA datasets available.

Common Searches

Search PubMed
Search Medline Plus
Search PubChem
Search CTD

Sources for PharmGKB drug information: DrugBank, PubChem.